gsk201504206k2.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending April 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--

 
 
GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline 2009 Performance Share Plan (the Plan) notified the Company and the under-mentioned Directors, Persons Discharging Managerial Responsibilities (PDMR) and Connected Persons on 17 April 2015 of the following increases in their notional interests in Ordinary Shares at a price of 1611.00 pence per Ordinary Share and American Depositary Shares (ADSs) at a price of $47.72 per ADS following the notional re-investment of the dividend paid to shareholders on 9 April 2015.
 
 
Director/PDMR
Ordinary Shares
ADSs
Sir Andrew Witty
19,261.141
 
Dr M M Slaoui
 
5,780.636
Mr S Dingemans
8,366.252
 
Mr R G Connor
3,751.573
 
Mr N Hirons
601.139
212.276
Mr S A Hussain
7,864.243
 
Mr W C Louv
 
1,695.701
Mr D S Redfern
2,852.896
 
Ms C Thomas
3,964.589
 
Mr P C Thomson
2,024.462
 
Mr D E Troy
 
3,596.168
Dr P J T Vallance
8,442.031
 
Ms E Walmsley
4,883.380
 
Mrs V A Whyte
532.249
 

 
Connected Person
Ordinary Shares
ADSs
Dr K Slaoui (connected person to Dr M M Slaoui)
 
93.510
Mrs K Thomson (connected person to Mr P C Thomson)
50.238
 

The notional dividends accrued will be paid out in proportion to the percentage of participants' Plan holdings that vest following the end of the relevant measurement period.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).



V A Whyte
Company Secretary
 
20 April 2015
 




 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: April 20, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc